Formoterol | CAS# 67346-48-9 | LABA

MedKoo Cat#: 564261 | Name: Formoterol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Formoterol is a long-acting beta-adrenergic receptor agonist (LABA).

Chemical Structure

Formoterol

CAS#67346-48-9 (free base)

Theoretical Analysis

MedKoo Cat#: 564261

Name: Formoterol

CAS#: 67346-48-9 (free base)

Chemical Formula: C19H24N2O4

Exact Mass: 344.1736

Molecular Weight: 344.41

Elemental Analysis: C, 66.26; H, 7.02; N, 8.13; O, 18.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

67346-48-9 (free base) 43229-80-7 (fumarate)

Synonym

(+)-Formoterol; (S,S)-Formoterol; Foradil; Formoterol

IUPAC/Chemical Name

N-[2-Hydroxy-5-[(1S)-1-hydroxy-2-[[(2S)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide

InChi Key

BPZSYCZIITTYBL-ORAYPTAESA-N

InChi Code

InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m0/s1

SMILES Code

O=CNC1=CC([C@H](O)CN[C@@H](C)CC2=CC=C(OC)C=C2)=CC=C1O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 344.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wauthoz N, Hennia I, Ecenarro S, Amighi K. Impact of capsule type on aerodynamic performance of inhalation products: a case study using a formoterol-lactose binary or ternary blend. Int J Pharm. 2018 Oct 12. pii: S0378-5173(18)30769-5. doi: 10.1016/j.ijpharm.2018.10.034. [Epub ahead of print] PubMed PMID: 30321640. 2: Lipworth BJ, Collier DJ, Gon Y, Zhong N, Nishi K, Chen R, Arora S, Maes A, Siddiqui S, Reisner C, Martin UJ. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018 Sep 26;13:2969-2984. doi: 10.2147/COPD.S171835. eCollection 2018. PubMed PMID: 30310273; PubMed Central PMCID: PMC6167125. 3: Scholpa NE, Williams H, Wang W, Corum D, Narang A, Tomlinson S, Sulllivan PG, Rabchevsky AG Ph.D, Schnellmann RG. Pharmacological stimulation of mitochondrial biogenesis using the FDA-approved β₂-adrenoreceptor agonist formoterol for the treatment of spinal cord injury. J Neurotrauma. 2018 Oct 3. doi: 10.1089/neu.2018.5669. [Epub ahead of print] PubMed PMID: 30280980. 4: Zheng J, Zhong N, Wang C, Huang Y, Chen P, Wang L, Hui F, Zhao L, Wang H, Luo L, Du X, Han Goh A, Lipson DA. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial). COPD. 2018 Sep 28:1-7. doi: 10.1080/15412555.2018.1481022. [Epub ahead of print] PubMed PMID: 30265816. 5: Stanbrook MB. As-needed budesonide-formoterol better controlled mild asthma vs terbutaline, but maintenance budesonide was better. Ann Intern Med. 2018 Sep 18;169(6):JC31. doi: 10.7326/ACPJC-2018-169-6-031. PubMed PMID: 30242404. 6: Stanbrook MB. As-needed budesonide-formoterol was noninferior to maintenance budesonide for exacerbations in mild asthma. Ann Intern Med. 2018 Sep 18;169(6):JC30. doi: 10.7326/ACPJC-2018-169-6-030. PubMed PMID: 30242403. 7: D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2805-2819. doi: 10.2147/COPD.S113306. eCollection 2018. Review. PubMed PMID: 30233171; PubMed Central PMCID: PMC6135066. 8: Backer V, Ellery A, Borzova S, Lane S, Kleiberova M, Bengtsson P, Tomala T, Basset-Stheme D, Bennett C, Lindner D, Meiners A, Overend T. Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management. Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618796987. doi: 10.1177/1753466618796987. PubMed PMID: 30232933; PubMed Central PMCID: PMC6149027. 9: Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16. Erratum in: Lancet Respir Med. 2018 Oct 4;:. PubMed PMID: 30232048. 10: Ferguson GT, Papi A, Anzueto A, Kerwin EM, Cappelletti C, Duncan EA, Nyberg J, Dorinsky P. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J. 2018 Sep 16;52(3). pii: 1801334. doi: 10.1183/13993003.01334-2018. Print 2018 Sep. PubMed PMID: 30220648.